Quantitative Whole Body Biodistribution of Fluorescent-Labeled Agents by Non-Invasive Tomographic Imaging

When small molecules or proteins are injected into live animals, their physical and chemical properties will significantly affect pharmacokinetics, tissue penetration, and the ultimate routes of metabolism and clearance. Fluorescence molecular tomography (FMT) offers the ability to non-invasively image and quantify temporal changes in fluorescence throughout the major organ systems of living animals, in a manner analogous to traditional approaches with radiolabeled agents. This approach is best used with biotherapeutics (therapeutic antibodies, or other large proteins) or large-scaffold drug-delivery vectors, that are minimally affected by low-level fluorophore conjugation. Application to small molecule drugs should take into account the significant impact of fluorophore labeling on size and physicochemical properties, however, the presents studies show that this technique is readily applied to small molecule agents developed for far-red (FR) or near infrared (NIR) imaging. Quantification by non-invasive FMT correlated well with both fluorescence from tissue homogenates as well as with planar (2D) fluorescence reflectance imaging of excised intact organs (r2 = 0.996 and 0.969, respectively). Dynamic FMT imaging (multiple times from 0 to 24 h) performed in live mice after the injection of four different FR/NIR-labeled agents, including immunoglobulin, 20–50 nm nanoparticles, a large vascular imaging agent, and a small molecule integrin antagonist, showed clear differences in the percentage of injected dose per gram of tissue (%ID/g) in liver, kidney, and bladder signal. Nanoparticles and IgG1 favored liver over kidney signal, the small molecule integrin-binding agent favored rapid kidney and bladder clearance, and the vascular agent, showed both liver and kidney clearance. Further assessment of the volume of distribution of these agents by fluorescent volume added information regarding their biodistribution and highlighted the relatively poor extravasation into tissue by IgG1. These studies demonstrate the ability of quantitative FMT imaging of FR/NIR agents to non-invasively visualize and quantify the biodistribution of different agents over time.

[1]  Vasilis Ntziachristos,et al.  In vivo tomographic imaging of near-infrared fluorescent probes. , 2002, Molecular imaging.

[2]  R. Weissleder,et al.  Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging , 2002, European Radiology.

[3]  Ralph Weissleder,et al.  Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.

[4]  R. Weissleder,et al.  In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. , 2004, Arthritis and rheumatism.

[5]  M. Hashida,et al.  Macromolecular Carrier Systems for Targeted Drug Delivery: Pharmacokinetic Considerations on Biodistribution , 1996, Pharmaceutical Research.

[6]  Sanjiv S Gambhir,et al.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.

[7]  Sharon Bloch,et al.  Monomolecular multimodal fluorescence-radioisotope imaging agents. , 2005, Bioconjugate chemistry.

[8]  Vasilis Ntziachristos,et al.  Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Vasilis Ntziachristos,et al.  Tomographic fluorescence imaging of tumor vascular volume in mice. , 2007, Radiology.

[10]  François Guillemin,et al.  Quantum dots in axillary lymph node mapping: Biodistribution study in healthy mice , 2008, BMC Cancer.

[11]  R. Weissleder,et al.  Noninvasive Optical Detection of Bone Mineral , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  James G. Fox,et al.  The Mouse in biomedical research , 2007 .

[13]  J. Schellens,et al.  Application of PET/CT in the development of novel anticancer drugs. , 2008, The oncologist.

[14]  G. Pelled,et al.  Fluorescence molecular tomography enables in vivo visualization and quantification of nonunion fracture repair induced by genetically engineered mesenchymal stem cells , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[15]  K. Wittrup,et al.  Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids , 2008, Molecular Cancer Therapeutics.

[16]  Youngho Seo Quantification of SPECT and PET for Drug Development , 2008 .

[17]  Ralph Weissleder,et al.  Hybrid In Vivo FMT-CT Imaging of Protease Activity in Atherosclerosis With Customized Nanosensors , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Peterson,et al.  Noninvasive Quantitative Tomography of the Therapeutic Response to Dexamethasone in Ovalbumin-Induced Murine Asthma , 2009, Journal of Pharmacology and Experimental Therapeutics.

[19]  Bahman Anvari,et al.  Biodistribution of encapsulated indocyanine green in healthy mice. , 2009, Molecular pharmaceutics.

[20]  Compensation of optical heterogeneity-induced artifacts in fluorescence molecular tomography: theory and in vivo validation. , 2009, Journal of biomedical optics.

[21]  Dong Liang,et al.  Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles , 2009, Nanotechnology.

[22]  M. Yaffe,et al.  Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function. , 2009, Arthritis and rheumatism.

[23]  A. Rosato,et al.  Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. , 2009, Nuclear medicine and biology.

[24]  Bohumil Bednar,et al.  Dual In Vivo Quantification of Integrin-targeted and Protease-activated Agents in Cancer Using Fluorescence Molecular Tomography (FMT) , 2010, Molecular Imaging and Biology.

[25]  H. Kruth,et al.  Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions. , 2009, The Journal of clinical investigation.

[26]  M. Tabrizi,et al.  Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease , 2010, The AAPS Journal.

[27]  G. Mittal,et al.  Radiolabeling, biodistribution and gamma scintigraphy of noscapine hydrochloride in normal and polycystic ovary induced rats , 2010, Journal of ovarian research.

[28]  K. Vasquez,et al.  Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis , 2010, Arthritis research & therapy.